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as entecavir and tenofovir have low risk of resistance, for
historical reasons many patients in Asia have been exposed
to drugs with low genetic barrier to resistance.
To detect drug resistance, vigilant monitoring of HBV DNA
level is essential. Virological breakthrough is deﬁned as a
rise of HBV DNA level by 10-fold during antiviral therapy
and is indicative of drug resistance. When virological
breakthrough develops, salvage antiviral therapy with a
drug without cross-resistance should be initiated as soon
as possible to ensure treatment success. Nevertheless, in
some cases the selection of salvage therapy is not always
straightforward. For example, while adefovir dipivoxil or
tenofovir is commonly used to treat lamivudine resistance,
the mutant rtA181T/V confers resistance or reduced
sensitivity to all three agents but remains sensitive to
entecavir.
Drug resistance testing is used to identify the culprit mutant
and aids clinicians in choosing the optimal antiviral agent. In
a recent survey, drug resistance testing altered management
in over half of the cases. Two types of commercial assays
are available direct sequencing (TRUGENE HBV, Siemens
Health Care Diagnostic Solutions, and Afﬁgene HBV DE/3TC
Assay, Sangtec Molecular Diagnostics AB) and reverse
hybridization (INNO-LiPA DR Version 2.0, Innogenetics).
Direct sequencing of the polymerase gene has the advantage
of identifying both known and previously unreported
mutations. However, the test may be falsely negative
if the mutants constitute less than 20% of the whole
population. Besides, the detection of new mutations is
common and may not necessarily represent drug resistance.
In vitro phenotypic analysis is required to conﬁrm decreased
susceptibility to treatment.
In contrast, hybridization assays are more sensitive and
can detect mutants that constitute only 5% of the
whole population. Nevertheless, one major limitation of
hybridization assays is that only known mutations can be
detected. When new drug-resistant mutations are reported,
the test needs regular updating.
Mass spectroscopy represents an inexpensive and sensitive
method that may detect mutant population that represents
5% of the overall population. Ultradeep pyrosequencing is
another more sensitive technique. These new technologies
may overcome the limitations of existing assays and warrant
further validation.
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Inﬂuenza continues to be a serious respiratory disease
globally and can become a major public health threat when
a novel virus with pandemic potential emerges. Classical
inﬂuenza presents with the sudden onset of fever followed
by systemic symptoms of muscle aches, malaise and a cough.
During an outbreak or epidemic, the accuracy of a clinician’s
diagnosis of inﬂuenza may have a PPV 79 87% and NPV
39 75%, while the PPV drops to 44% during periods of low
activity. Atypical presentations may also occur especially in
young children and the elderly, and the severity of symptoms
may vary from mild to severe. Further other viral infections
can present as inﬂuenza-like-illness. For these reasons, the
laboratory diagnosis of inﬂuenza may be required to assist
the antiviral treatment and management of patients in the
community and in hospital.
Many laboratories have focused on molecular diagnostics
(nucleic acid ampliﬁcation) following the avian inﬂuenza
outbreak in late 2003, then the H1N1 2009 pandemic,
because of this technologies high sensitivity, speciﬁcity,
potential for automation and staff safety considerations.
The perceived cost, minimum sample volume requirements
for batched testing using commercial platforms, and
the requirement for trained staff to ensure quality and
maintenance procedures are followed, has limited the
introduction of this technology into some laboratories.
Classical diagnostic methods involve the culture of
viable virus and the direct detection of viral antigen
by immunoﬂuoresence or immunocromatography assays.
Culture remains the gold standard, while the sensitivity
and speciﬁcity of antigen detection assays is limited by
the technology used, and their clinical usefulness (PPV and
NPV) is inﬂuenced by the level of inﬂuenza activity in the
community. An important consideration is the diagnostic
yield of inﬂuenza detection assays which can be affected
by a number of factors including the natural course of viral
shedding during an infection, the severity of disease, the
timing of a patient’s presentation for sampling and the type
and quality of respiratory sample obtained.
The role of the laboratory has changed following the recent
H1N1 pandemic. Public Health specialists now require
both positive and negative results in a timely manner to
assist the management of outbreaks. Clinicians also require
inﬂuenza A subtype and antiviral resistance information, all
of which requires the use of sensitive molecular assays.
The renewed focus on inﬂuenza surveillance has raised
the importance of other non-inﬂuenza respiratory viruses
and their detection. There are an increasing range of
commercial assays becoming available utilizing differing
molecular methods and primer designs. These automated
fully validated assays, with quality controlled reagents and
the auto-calling of results offer increased sensitivity and
rapid turnaround times for the detection of a wide range
of respiratory viruses. Few head-to-head comparisons are
available to allow assessment of their clinical usefulness.
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Inﬂuenza pandemics cause signiﬁcant human mortality. In
the 20th Century there were three recorded pandemics that
resulted in over 50 million human deaths. During March
and early April 2009, an H1N1 virus lineage previously
undetected in humans emerged in Mexico and the United
States. This novel virus was sufﬁciently antigenically
divergent from seasonal H1N1 that the human population
was immunologically naive. Subsequently this virus spread
rapidly via human-to-human transmission, developing into
the ﬁrst inﬂuenza pandemic in 40 years. Despite global
concern regarding pandemic inﬂuenza, the emergence
pathways of pandemic strains remained obscure. Here
the evolutionary history and inferred date of introduction
to humans of each of the genes for all four pandemic
inﬂuenza strains were calculated. Phylogenetic trees were
inferred using the neighbor-joining distance method, with
genetic distances calculated by maximum likelihood under
the Hasegawa Kishino Yano (HKY) model with gamma-
distributed rates among sites. Parameters of this model
were estimated using maximum likelihood on an initial
tree. Temporal phylogenies and rates of evolution were
inferred using a relaxed molecular clock model that allows
rates to vary among lineages within a Bayesian Markov
chain Monte Carlo (MCMC) framework. A model comprising
